Table 4.
Top 20 cited articles on CHB treatment.
| Title | Author | Journal | Year | Total Cited |
|---|---|---|---|---|
| Lamivudine as initial treatment for chronic hepatitis B in the United States21 | Dienstag JL, Schiff ER, Wright TL, et al. | New England Journal of Medicine | 1999 | 1105 |
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B22 | Marcellin P, Chang T, Lim SG, et al. | New England Journal of Medicine | 2003 | 1057 |
| Effect of alpha-interferon treatment in patients with hepatitis-B e-antigen-positive chronic hepatitis-B – a meta analysis23 | Wong DKH, Cheung AM, Orourke K, et al. | Annals of Internal Medicine | 1993 | 865 |
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B24 | Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. | New England Journal of Medicine | 2003 | 763 |
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years25 | Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. | Gastroenterology | 2006 | 685 |
| A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B26 | Perrillo RP, Schiff ER, Davis GL, et al. | New England journal of Medicine | 1990 | 684 |
| Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study27 | Marcellin P, Gane E, Buti M, et al. | Lancet | 2013 | 682 |
| Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B28 | Niederau C, Heintges T, Lange S, et al. | New England Journal of Medicine | 1996 | 670 |
| Long-term safety of lamivudine treatment in patients with chronic hepatitis B29 | Lok ASF, Lai CL, Leung N, et al. | Gastroenterology | 2003 | 621 |
| Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B30 | Liaw YF, Leung NWY, Chang TT, et al. | Gastroenterology | 2000 | 620 |
| Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy31 | Werle-Lapostolle B, Bowden S, Locarnini S, et al. | Gastroenterology | 2004 | 602 |
| AASLD guidelines for treatment of chronic hepatitis B32 | Terrault NA, Bzowej N H, Chang K-M, et al. | Hepatology | 2016 | 597 |
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy33 | Leung NWY, Lai CL, Chang TT, et al. | Hepatology | 2001 | 542 |
| Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B34 | Chang TT, Liaw YF, Wu SS, et al. | Hepatology | 2010 | 541 |
| Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B35 | Lai CL, Dienstag J, Schiff E, et al. | Clinical Infectious Diseases | 2003 | 518 |
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B36 | Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. | New England Journal of Medicine | 2005 | 453 |
| Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial37 | Schalm SW, Heathcote J, Cianciara J, et al. | Gut | 2000 | 427 |
| Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B38 | Boni C, Bertoletti A, Penna A, et al. | Journal of Clinical Investigation | 1998 | 380 |
| A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update39 | Keeffe EB, Dieterich DT, Han S-H, et al. | Clinical Gastroenterology and Hepatology | 2008 | 376 |
| Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B40 | Villeneuve JP, Condreay LD, Willems B, et al. | Hepatology | 2000 | 374 |
CHB, chronic hepatitis B.